On the other hand, melatonin receptor agonist, ramelteon, antagonized the PTSD-like behaviors in Fabp3 null mice, and therefore, we suggest that melatonin receptors may be a novel therapeutic target and ramelteon can be an effective drug candidate for the PTSD symptoms. The gene discussed is FABP3; the disease is post-traumatic stress disorder.